鹿血晶治疗肿瘤化疗所致血小板减少症的临床疗效观察
发布时间：2018-10-09 18:07
【摘要】：目的:观察鹿血晶治疗肿瘤化疗所致血小板减少症的临床疗效。材料与方法:符合条件的50例患者(1.经组织学或细胞学检查诊断的恶性肿瘤需化疗的患者;2.住院患者,经一周期化疗后血小板降低至(25.0-75.0)×109/L;3.需要继续接受至少两个周期以上相同化疗方案,剂量调整不超过±10%;4.男女不限,年龄在18-70岁;5.肝肾功等检查基本正常;6.ECOG评分≤2分;7.预计生存期大于3个月。)随机分为TPO组和TPO+鹿血晶组,各25例。TPO组:使用TPO 1.5万U,每日一次,皮下注射,TPO+鹿血晶组:使用TPO 1.5万U,每日一次,皮下注射联合鹿血晶1g,每日三次,口服,两组观察时间最长均为14d,观察血小板计数、白细胞、红细胞、生命体征、中医主要症状、肝肾功能、凝血功能及经济费用等。结果:1.两组临床疗效有差异,统计学有意义(P0.05);2.两组各自治疗前后血小板计数比较差异统计学有意义(P0.05),两组组间治疗前血小板计数、治疗后血小板计数、血小板计数持续50×109/L天数、血小板恢复至100×109/L所需天数对比差异统计学没有意义(P0.05);3.TPO组治疗前后白细胞,两组治疗前后红细胞、中性粒细胞对比统计学没有意义(P0.05),而TPO+鹿血晶组治疗前后白细胞对比差异统计学有意义(P0.05);4.在中医主要症状中,两组在神疲乏力、心悸气短、睡眠等症状对比差异统计学有意义(P0.05),在头晕目眩、纳呆食少、腰膝酸软、自汗盗汗等症状对比差异统计学没有意义(P0.05);5.所有患者均未发生明显的药物不良反应。结论:鹿血晶联合TPO升血小板疗效优于单药TPO,并能缩短肿瘤化疗所致血小板减少症的治疗时间,鹿血晶能改善患者神疲乏力、心悸气短、睡眠等症状,且安全性良好。
[Abstract]:Objective: to observe the clinical effect of Luxuejing on thrombocytopenia induced by tumor chemotherapy. Materials and methods: 50 eligible patients (1. 5%). Patients with malignant tumors diagnosed by histology or cytology need chemotherapy. In inpatients, after one cycle of chemotherapy, platelets decreased to (25.0-75.0) 脳 109 / L ~ (3). Need to continue to receive at least two cycles of the same chemotherapy regimen, dose adjustment does not exceed 卤10 ~ 4. Men and women do not limit, the age of 18 to 70 years old or 5. 6. ECOG score 鈮，
本文编号：2260271
[Abstract]:Objective: to observe the clinical effect of Luxuejing on thrombocytopenia induced by tumor chemotherapy. Materials and methods: 50 eligible patients (1. 5%). Patients with malignant tumors diagnosed by histology or cytology need chemotherapy. In inpatients, after one cycle of chemotherapy, platelets decreased to (25.0-75.0) 脳 109 / L ~ (3). Need to continue to receive at least two cycles of the same chemotherapy regimen, dose adjustment does not exceed 卤10 ~ 4. Men and women do not limit, the age of 18 to 70 years old or 5. 6. ECOG score 鈮，
本文编号：2260271
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2260271.html
